TY - JOUR
T1 - Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma
AU - Balushi, Khalid Al
AU - Hadhrami, Abdulrahman Al
AU - Balushi, Hamdan Al
AU - Das, Srijit
AU - Lawati, Abdullah Al
N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
PY - 2023/12/19
Y1 - 2023/12/19
N2 - Uveal melanoma (UM) is the most common primary intraocular malignancy in adults and commonly occurs in the Caucasian population. The malignancy involves the uvea of the eye, which includes the iris, ciliary body, and choroid. The etiology of UM is still not well understood, but age is a risk factor. Symptoms include blurred vision, redness of the eye, floaters, dark spots, a change in the size of the pupil, and loss of vision. The location, shape, and size of the tumor are important for therapeutic purposes. Treating metastasis is always a challenge in UM cases. In cases of lung metastasis, the survival rate decreases. Treatment includes surgery, laser therapy, immunotherapy, hormone therapy, and chemotherapy. Recently, in 2022, the United States Food and Drug Administration (FDA) approved the drug tebentafusp. Tebentafusp was developed to target the most common HLA complex in humans. The present review discusses the indications for the use of a new drug tebentafusp, its mechanism of action, dose, pharmacokinetics, results of clinical trials conducted, and adverse effects like cytokine release syndrome. Hence, tebentafusp is the first T cell receptor (TCR) therapeutic drug that could be considered for the treatment of UM.
AB - Uveal melanoma (UM) is the most common primary intraocular malignancy in adults and commonly occurs in the Caucasian population. The malignancy involves the uvea of the eye, which includes the iris, ciliary body, and choroid. The etiology of UM is still not well understood, but age is a risk factor. Symptoms include blurred vision, redness of the eye, floaters, dark spots, a change in the size of the pupil, and loss of vision. The location, shape, and size of the tumor are important for therapeutic purposes. Treating metastasis is always a challenge in UM cases. In cases of lung metastasis, the survival rate decreases. Treatment includes surgery, laser therapy, immunotherapy, hormone therapy, and chemotherapy. Recently, in 2022, the United States Food and Drug Administration (FDA) approved the drug tebentafusp. Tebentafusp was developed to target the most common HLA complex in humans. The present review discusses the indications for the use of a new drug tebentafusp, its mechanism of action, dose, pharmacokinetics, results of clinical trials conducted, and adverse effects like cytokine release syndrome. Hence, tebentafusp is the first T cell receptor (TCR) therapeutic drug that could be considered for the treatment of UM.
KW - drug
KW - etiology
KW - malignant
KW - tebentafusp
KW - treatment
KW - tumor
KW - Uveal melanoma
UR - http://www.scopus.com/inward/record.url?scp=85184836857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184836857&partnerID=8YFLogxK
U2 - 10.2174/0113894501280380231214105255
DO - 10.2174/0113894501280380231214105255
M3 - Article
C2 - 38115619
SN - 1389-4501
VL - 25
SP - 149
EP - 157
JO - Current Drug Targets
JF - Current Drug Targets
IS - 3
ER -